Skip to main content

TSR-042 and Radiation for the Treatment of Stage I-II Endometrial Cancer

Trial Status: Active

This phase I trial studies the side effects of TSR-042 and radiation in treating stage I-II endometrial cancer. Immunotherapy with TSR-042, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving TSR-042 in combination with radiation therapy may work better in treating patients with endometrial cancer compared to radiation therapy alone.

Inclusion Criteria

  • Newly diagnosed biopsy proven Federation of Gynecology and Obstetrics (FIGO) clinical stage I or II endometrial carcinoma
  • Histology of FIGO grade 1-3 endometrioid endometrial carcinoma
  • Medically inoperable per treating gynecologic oncologist
  • Candidate for definitive radiation therapy as determined by treating radiation oncologist
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Absolute neutrophil count >= 1,500/uL
  • Platelets >= 100,000/uL
  • Hemoglobin >= 9 g/dL; transfusion is allowed to meet this criterion
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance 60 mL/min using the Cockcroft-Gault equation
  • Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome) OR direct bilirubin =< 1 x ULN
  • Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN
  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Participant receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to initiating protocol therapy
  • Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment
  • Female participant has a negative serum pregnancy test the day of and prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of non-childbearing potential. Non-childbearing potential is defined as follows (by other than medical reasons): * >= 45 years of age and has not had menses for > 1 year * Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation * Post-bilateral oophorectomy, or post-tubal ligation. Documented oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Information must be captured appropriately within the site’s source documents * Note: Abstinence is acceptable if this is the established and preferred contraception for the patient
  • Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment
  • Ability to understand and willingness to sign an Institutional Review Board (IRB) approved written informed consent document (or that of legally authorized representative, if applicable)

Exclusion Criteria

  • Any prior treatment for endometrial cancer or currently receiving chemotherapy for endometrial cancer
  • Evidence of metastatic disease outside of the cervix or uterus as determined on computed tomography (CT) or magnetic resonance imaging (MRI)
  • History of other malignancy =< 3 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only
  • Previous treatment with an anti-PD-1, anti-PD-L1, or any PD-L2 drug
  • Known brain or leptomeningeal metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to TSR-042 or other agents used in the study
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry
  • Participant must not be simultaneously enrolled in any interventional clinical trial
  • Participant must not have had major surgery =< 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
  • Participant must not have received investigational therapy =< 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy
  • Participant has had radiation therapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy
  • Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
  • Patient experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy, with the exception of non-clinically significant lab abnormalities
  • Participant has a diagnosis of immunodeficiency or has receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy
  • Participant has a known history of human immunodeficiency virus (type 1 or 2 antibodies)
  • Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)
  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunomodulatory drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Participant must not have a history of interstitial lung disease
  • Participant has received a live vaccine within 14 days of initiating protocol therapy


Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE
Contact: Stephanie Markovina
Phone: 314-747-1786


I. To evaluate the safety and tolerability of anti-PD-1 monoclonal antibody TSR-042 (TSR-042) in combination with concurrent internal radiation therapy (brachytherapy) +/- pelvic radiation.


I. To determine progression-free survival at two years in patients with high risk inoperable endometrial carcinoma who have received TSR-042 with concurrent brachytherapy +/- pelvic radiation.


Patients receive anti-PD-1 monoclonal antibody TSR-042 intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in week 1 of cycle 2, patients also undergo brachytherapy weekly for 6 weeks. Patients may also undergo external beam radiation therapy 4 days a week for 7 weeks at the discretion of treating physician.

After completion of study treatment, patients are followed up at 30 days, 6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Siteman Cancer Center at Washington University

Principal Investigator
Stephanie Markovina

  • Primary ID 201907060
  • Secondary IDs NCI-2019-05814
  • ID NCT03955978